ZyVersa Therapeutics, Inc. (ZVSA) reported Loss for second quarter of -$2.211 million The company's bottom line came in at -$2.211 million, or -$0.46 per share. This compares with -$2.763 million, or -$3.31 per share, last year. ZyVersa Therapeutics, Inc. earnings at a glance (GAAP) : -Earnings:...
ZyVersa Therapeutics, Inc. (ZVSA), a clinical-stage biopharma firm focused on renal and inflammatory diseases, has entered into a warrant inducement agreement with a single institutional investor. The agreement allows for the immediate exercise of Series A-2 and A-3 Warrants, covering 957,200 and...
ZyVersa Therapeutics Inc. (ZVSA), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases, announces newly published data supporting the potential of its Inflammasome ASC Inhibitor IC 100 to slow the progression of Parkinson's...
ZyVersa Therapeutics (ZVSA), Wednesday announced that newly published data support the potential of its inflammasome ASC Inhibitor, IC 100, in treating Alzheimer's disease or AD. The data, published in Immunity, demonstrate that NLRP3 inhibition with IC 100 reduced neuroinflammation and amyloid beta...
ZyVersa Therapeutics, Inc. (ZVSA) has announced new data showing that its Inflammasome ASC Inhibitor IC 100 significantly improves heart function, reduces inflammation, and restores glucose homeostasis in an obese animal model of heart failure with preserved ejection fraction or HFpEF and type 2 diabetes....
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.